Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Vestal Point Capital LP

Vestal Point Capital LP lowered its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 15.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 425,000 shares of the company’s stock after selling 75,000 shares during the period. Vestal Point Capital LP’s holdings in Nurix Therapeutics were worth $9,550,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Amalgamated Bank raised its holdings in shares of Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after acquiring an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares during the last quarter. International Assets Investment Management LLC grew its holdings in shares of Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after buying an additional 4,119 shares in the last quarter. Finally, Quest Partners LLC raised its position in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NRIX. HC Wainwright raised their target price on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada lowered their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Robert W. Baird initiated coverage on Nurix Therapeutics in a research note on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a report on Wednesday, November 6th. Finally, Stephens reiterated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.40.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 9,050 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $24.94, for a total value of $225,707.00. Following the transaction, the insider now owns 24,592 shares in the company, valued at $613,324.48. The trade was a 26.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 2,368 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the completion of the transaction, the chief financial officer now directly owns 37,270 shares of the company’s stock, valued at approximately $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,451 shares of company stock valued at $663,160 over the last 90 days. 7.20% of the stock is owned by corporate insiders.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $21.23 on Friday. The firm’s fifty day simple moving average is $24.09 and its 200 day simple moving average is $21.70. Nurix Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.